Publication: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Loading...
Program
relationships.isAuthorOf
Author
Sezer, Ahmet
Kilickap, Saadettin
Gümüş, Mahmut
Bondarenko, Igor
Özgüroğlu, Mustafa
Gogishvili, Miranda
Turk, HACI MEHMET
Bentsion, Dmitry
Gladkov, Oleg
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Description
Source
Keywords
Keywords
Citation
Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.-, Lancet (London, England), cilt.397, ss.592-604, 2021